Related Experiment Videos

[Side effects of antithrombotic treatment in the secondary prevention of cerebrovascular disease]

A P Sempere1, M Ferrero, M L Tahoces

  • 1Servicio de Neurología, Hospital General de Segovia, España. aperezs@meditex.es

Revista De Neurologia
|April 1, 2000
PubMed

Insights

Antithrombotic drugs like aspirin and ticlopidine are generally well-tolerated in patients with transient ischemic attacks (TIA) and mild ischemic strokes (IL). However, aspirin use is linked to gastrointestinal bleeding and cerebral hemorrhage, impacting overall tolerance.

Area of Science:

  • Neurology
  • Pharmacology
  • Cardiovascular Medicine

Context:

  • Transient ischemic attacks (TIA) and mild ischemic strokes (IL) are critical neurological events requiring preventative treatment.
  • Antithrombotic therapies, including antiplatelets and anticoagulants, are standard care for TIA and IL patients.
  • Understanding the adverse effect profile of these drugs is crucial for optimizing patient management.

Purpose:

  • To determine the incidence and nature of adverse effects associated with antithrombotic drug use in patients diagnosed with TIA and mild IL.
  • To compare the safety profiles of different antithrombotic agents, specifically aspirin, ticlopidine, and acenocumarol.

Summary:

  • A community-based observational study followed 235 patients (average age 70.8 years) for 3.6 years, analyzing adverse effects of aspirin, ticlopidine, and acenocumarol.
  • Overall, 6% of patients experienced adverse effects leading to treatment suspension: 5% for aspirin and acenocumarol, and 17% for ticlopidine.
  • Aspirin was associated with significant hemorrhagic complications (2.8% digestive tract bleeding, 1.7% cerebral hemorrhage), while ticlopidine's effects were generally mild.

Impact:

  • The findings indicate that while antithrombotic drugs are generally safe for TIA and IL patients, hemorrhagic complications, especially with aspirin, necessitate careful monitoring.
  • This data can inform clinical decision-making regarding the choice and duration of antithrombotic therapy to balance efficacy and safety.
  • Further research into mitigating aspirin-related bleeding risks could enhance long-term patient outcomes.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...